Scholarlink

<p>Mangiferin, a bioactive xanthonoid predominantly present in mango, exhibits significant therapeutic potential in metabolic disorders, particularly diabetes mellitus. The present study was undertaken to compare the inhibitory potential of mangiferin with the standard drug acarbose against the carbohydrate hydrolyzing enzymes <i>α-glucosidase</i> and <i>α-amylase</i> using an integrated biochemical and in silico approach. Mangiferin was quantified in pulp and peel using LC-MS/MS analysis, revealing significant varietal variation, with Zardalu pulp (3.80 ± 0.2&#xa0;mg/kg DW) and Dasheri peel (7.99 ± 0.2&#xa0;mg/kg DW) showing the highest concentrations. Biochemical profiling demonstrated higher phenolic and flavonoid content in mango peels compared to pulp, indicating their potential as rich sources of bioactive compounds. Molecular docking analysis was performed using an AutoDock based workflow followed by residue-residue interaction analysis to evaluate ligand-protein interactions. Molecular docking analysis revealed strong binding affinity of mangiferin with <i>α-glucosidase</i> (-7.1&#xa0;kcal/mol) and <i>α-amylase</i> (-8.4&#xa0;kcal/mol), in comparison to standard drug acarbose. Interaction analysis showed stable hydrogen bonding, hydrophobic interactions and π-π stacking with key catalytic residues, suggesting effective inhibition of carbohydrate hydrolyzing enzymes. Structural validation using Ramachandran plot confirmed the reliability of protein models. These findings indicate that mangiferin exhibits a comparatively stronger binding affinity towards <i>α-amylase</i> than acarbose and may serve as a promising natural antidiabetic agent. The integration of biochemical and in silico findings highlights mango, as a promising source of natural antidiabetic compounds. However, further in vitro and in vivo studies are required to validate its therapeutic applicability.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Mangiferin as a Polyphenolic Scaffold for Enzyme Targeted Molecular Regulation of Carbohydrate Hydrolyzing Enzymes in Diabetes Management

  • 期刊论文

  • 发表日期：

    2026年7月7日

查看全文
  • V Shajeeda Banu,
  • Mohammed Wasim Siddiqui,
  • Deep Lata,
  • Pritam Ganguly,
  • Duniya Ram Singh

摘要

Mangiferin, a bioactive xanthonoid predominantly present in mango, exhibits significant therapeutic potential in metabolic disorders, particularly diabetes mellitus. The present study was undertaken to compare the inhibitory potential of mangiferin with the standard drug acarbose against the carbohydrate hydrolyzing enzymes α-glucosidase and α-amylase using an integrated biochemical and in silico approach. Mangiferin was quantified in pulp and peel using LC-MS/MS analysis, revealing significant varietal variation, with Zardalu pulp (3.80 ± 0.2 mg/kg DW) and Dasheri peel (7.99 ± 0.2 mg/kg DW) showing the highest concentrations. Biochemical profiling demonstrated higher phenolic and flavonoid content in mango peels compared to pulp, indicating their potential as rich sources of bioactive compounds. Molecular docking analysis was performed using an AutoDock based workflow followed by residue-residue interaction analysis to evaluate ligand-protein interactions. Molecular docking analysis revealed strong binding affinity of mangiferin with α-glucosidase (-7.1 kcal/mol) and α-amylase (-8.4 kcal/mol), in comparison to standard drug acarbose. Interaction analysis showed stable hydrogen bonding, hydrophobic interactions and π-π stacking with key catalytic residues, suggesting effective inhibition of carbohydrate hydrolyzing enzymes. Structural validation using Ramachandran plot confirmed the reliability of protein models. These findings indicate that mangiferin exhibits a comparatively stronger binding affinity towards α-amylase than acarbose and may serve as a promising natural antidiabetic agent. The integration of biochemical and in silico findings highlights mango, as a promising source of natural antidiabetic compounds. However, further in vitro and in vivo studies are required to validate its therapeutic applicability.